Most patients discover cancer only when it has already advanced
In a country where colorectal cancer quietly claims tens of thousands of lives each year — most of them diagnosed too late — Brazil's public health system has chosen a different path forward. The Health Ministry has adopted the immunochemical fecal test as its standard screening protocol for the SUS, extending the possibility of early detection to more than 40 million Brazilians between the ages of 50 and 75. It is a decision rooted in both clinical evidence and demographic urgency, arriving at a moment when projections warn that deaths from the disease could nearly triple by 2030 if the arc of late-stage diagnosis is not bent.
- Colorectal cancer is Brazil's second most common cancer, with 53,800 new cases projected annually through 2028 and a mortality rate poised to triple by 2030 — driven largely by diagnoses arriving too late to treat effectively.
- The FIT test cuts through a key barrier: it requires no dietary restrictions, no intestinal preparation, and no clinic visit — just a home stool sample, making it far more likely that people will actually complete it.
- With 85–92% sensitivity, the test detects microscopic blood that may signal polyps or early-stage cancer, triggering follow-up colonoscopies before lesions become malignant.
- Conitec, Brazil's official body for evaluating medical technologies in the public system, granted formal approval in March 2026 — grounding the policy shift in expert consensus rather than political expediency.
- The protocol is now in place, but its true test lies ahead: whether implementation reaches all 40 million eligible Brazilians quickly enough to reverse a mortality trajectory already in motion.
Brazil's Health Ministry announced this week that the immunochemical fecal test — known as FIT — will become the standard colorectal cancer screening tool across the Sistema Único de Saúde, the country's unified public health network. The protocol targets asymptomatic men and women between 50 and 75, a population the ministry estimates at more than 40 million people.
The test works simply: patients collect a small stool sample at home, with no special preparation or dietary restrictions required. A laboratory then uses antibodies to detect microscopic traces of blood — the kind invisible to the naked eye but potentially indicative of polyps, precancerous lesions, or cancer. With a sensitivity rate between 85 and 92 percent, a positive result triggers a colonoscopy, allowing doctors to identify and remove problematic growths before they turn malignant.
The urgency behind the decision is stark. Colorectal cancer is already Brazil's second most common cancer, with roughly 53,800 new cases projected each year through 2028. Deaths are expected to nearly triple by 2030 — a trajectory driven by the fact that most patients are currently diagnosed only after the disease has advanced to stages where treatment is far less effective.
FIT addresses a practical barrier that older screening methods could not. Its simplicity and non-invasive nature tend to produce higher participation rates among the general population, effectively democratizing access to that critical first step in detection. The shift was not made lightly: in March 2026, Conitec — the national body that evaluates medical technologies for the public system — gave its formal clinical endorsement.
The framework is now in place. What remains to be seen is how swiftly and thoroughly the test reaches those 40 million eligible Brazilians, and whether early detection can meaningfully reverse a mortality curve that, without intervention, points sharply upward.
Brazil's Health Ministry took a significant step this week in the fight against colorectal cancer, announcing that the public health system will now use a new screening test as its standard protocol for detecting the disease early. The immunochemical fecal test—known by its English acronym FIT—will become the primary tool for screening asymptomatic men and women between the ages of 50 and 75 across the entire Sistema Único de Saúde, the country's unified public health network.
The test itself is straightforward. A patient receives a collection kit to use at home, gathering a small stool sample without any special preparation or dietary restrictions. That sample then goes to a laboratory, where the FIT uses specific antibodies to detect microscopic traces of blood invisible to the naked eye—the kind of bleeding that might signal polyps, precancerous lesions, or cancer itself. The test boasts a sensitivity rate between 85 and 92 percent, meaning it catches the vast majority of cases where something is actually wrong. If blood is detected, the patient moves on to more definitive imaging, typically a colonoscopy, which allows doctors to see the colon and rectum directly and remove problematic growths before they become malignant.
What makes this shift significant is both its scope and its timing. The ministry estimates that more than 40 million Brazilians could gain access to early detection through this new protocol—a massive expansion of preventive care. The urgency behind the decision is sobering. Colorectal cancer is already the second most common cancer in Brazil, excluding non-melanoma skin tumors. The National Cancer Institute projects roughly 53,800 new cases each year through 2028. Without intervention, deaths from the disease are expected to nearly triple by 2030. The reason mortality remains so high is grimly straightforward: most patients discover they have cancer only when it has already advanced to later stages, when treatment becomes far more difficult and outcomes far worse.
The FIT test addresses a real barrier to screening. Unlike older blood-detection methods, it requires no intestinal preparation, no restrictive diet beforehand, and can be completed with a single sample. It is less invasive than colonoscopy and, crucially, tends to have higher uptake among the general population—people are more willing to do it. The test essentially democratizes access to the first crucial step in the screening process, making it possible for millions who might otherwise skip preventive care to at least get an initial assessment.
The decision did not arrive without expert scrutiny. Specialists developed the new guidelines, and in March of this year, the National Commission for Technology Incorporation in SUS—the official body that evaluates new medical technologies for the public system—gave its formal approval. That endorsement matters. It signals that this is not a political gesture but a clinically sound shift grounded in evidence and expert consensus.
What happens next depends on implementation. The test is now the standard; the question is how quickly and thoroughly it reaches the 40 million eligible Brazilians, how many actually use it, and whether early detection through FIT truly begins to bend the curve on late-stage diagnoses. The machinery is in place. Whether it moves fast enough to prevent the projected surge in deaths remains to be seen.
Citações Notáveis
Most patients discover they have cancer only when it has already advanced to later stages, when treatment becomes far more difficult and outcomes far worse.— Health Ministry analysis of current screening patterns
A Conversa do Hearth Outra perspectiva sobre a história
Why does Brazil need a new screening test right now? Wasn't there already a way to check for this?
There was, but the old blood-detection tests were less precise and required more preparation. More importantly, most people weren't getting screened at all. Deaths are projected to triple by 2030 because people find out too late.
So this FIT test is easier to do?
Much easier. You collect a sample at home, no special diet, no fasting. That matters enormously when you're trying to reach 40 million people.
How accurate is it?
It catches 85 to 92 percent of cases where something is actually wrong. It's not perfect, but it's good enough to be the first filter—if it finds blood, you move to colonoscopy, which is definitive.
And colonoscopy is still the gold standard?
Yes. FIT is the screening tool. Colonoscopy is what you do when FIT says there's something to look at. That's when doctors can actually remove polyps before they turn into cancer.
Who approved this?
The National Commission for Technology Incorporation in SUS gave formal approval in March. It wasn't rushed—specialists developed the guidelines and the experts signed off.
What's the real barrier now?
Getting it into people's hands and getting them to actually use it. The test exists. The system exists. The question is whether implementation happens fast enough to prevent the deaths that are coming.